Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-Patient: Convalescent Plasma for Moderate to Severe COVID-19
NCT04516811Phase 3Terminated
- Sponsor
- South African National Blood Service
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by South African National Blood Service. Started Sep 2020; status: terminated.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04516811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516811.